Abstract
Monoclonal antibodies are effective therapies for many disorders, but their nature and use continues to evolve as technologies emerge to improve their drug-like qualities. In this issue of Structure, Schmitz and colleagues report on structural and biophysical characterizations of single-domain "nanobodies" from llamas that target the epidermal growth factor receptor by both old and new mechanisms.
Original language | English (US) |
---|---|
Pages (from-to) | 1072-1073 |
Number of pages | 2 |
Journal | Structure |
Volume | 21 |
Issue number | 7 |
DOIs | |
State | Published - Jul 2 2013 |
Externally published | Yes |
ASJC Scopus subject areas
- Structural Biology
- Molecular Biology